JC02 Rec'd PCT/PTO 24 JUN 2005

Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. ATTTORNEY'S DOCKET NUMBER TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

3998-051955

CONCERNING A SUBMISSION UNDER 35 U.S.C. 371								
	IONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED 24.12.2002 (December 24, 2002)					
PCT/CA2003/002008 24.12.2003 (December 24, 2003) 24.12.2002 (December 24, 2002) TITLE OF INVENTION								
Encapsulated Cell Therapy								
APPLICANT(S) FOR DO/EO/US								
Duncan J. STEWART, David COURTMAN and Golnaz KAROUBI Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1. This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.								
	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.							
з. 🔲 т	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items							
<u> </u>	(5), (6), (9) and (21) indicated below. The US has been elected (Article 31)							
5.	The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)).							
J. 📺	A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is attached hereto (required only if not communicated by the International Bureau).							
	b. has been communicated by	· · · · · · · · · · · · · · · · · · ·						
			ing Office (RO/US).					
6 \square	c is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).							
· _	a. is attached hereto.							
		ted under 35 U.S.C. 154(d)(4).						
7. V	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))							
	a. are attached hereto (required only if not communicated by the International Bureau).							
	b. have been communicated by the International Bureau.							
	c. have not been made; however, the time limit for making such amendments has NOT expired.							
*	d. have not been made and will not be made.							
8.	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9. 🔲	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
10.	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).							
Items	11 to 20 below concern document(s	or information included:						
11.	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
12	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
13.	A preliminary amendment.							
14. 📙	An Application Data Sheet under 37 CFR 1.76.							
15.	A substitute specification.							
16	A power of attorney and/or change of address letter.							
17.	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.							
18.	A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
19	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).							
I an I	Other items or information:							

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2

JC09 Rec'd PCT/PTO 24 JUN 2005

PTO-1390 (Rev. 02-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION	ON NO. (if know	ATTORNEY'S DOCKET NUMBER					
	10/5/1 Inglees 5ve	3998-051955					
The follo	ving lees have l	CALCULATIONS	PTO USE ONLY				
21. Basic national fee\$300				\$300	\$ 300.00		
If International pro	1)-(4)	\$ 200.00					
23. Search fee (37 CF Internation International Sear All other situations	R 1.445(a)(2)) h al Searching Au ch Report prepa	\$ 400.00					
,	OTAL OF 21, 2	\$ 900.00					
Additional fee sequence list	for specification ing or computer 50 for each addi						
Total Sheets	Extra Sheets		ch additional 50 or fraction up to a whole number)	RATE	0		
- 100 =	/50 =	:		× \$250	\$		
Surcharge of \$130 claimed priority da			laration later than 30 months	from the earliest	\$ 130.00		
CLAIMS	NUME	BER FILED	NUMBER EXTRA	RATE	\$		
Total claims	3	7 - 20 =	17	× \$ 50	\$ 850.00		
Independent claim	S 4	- 3 =	1	× \$200	\$ 200.00		
MULTIPLE DEPE	NDENT CLAIM(S) (if applicable)		+ \$360	\$ 0		
		\$ 2,080.00					
Applicant clair	ms small entity s	0					
		\$ 2,080.00					
Processing fee of claimed priority da		\$ O					
		\$ 2,080.00					
Fee for recording by an appropriate		\$ 0					
		\$ 2,080.00					
		Amount to be refunded:	\$				
					Amount to be charged:	\$	
a. A check in the amount of \$ 2,080.00 to cover the above fees is enclosed.							
b. Please charge my Deposit Account No in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.							
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit t Account No. 23-0650 . A duplicate copy of this sheet is enclosed.							
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.							
SEND ALL CORRESPONDENCE TO:							
William H. Log		man					
Webb Ziesen	neim Logsdor	kar Wood Bh D					
400 Seventif Avenue, 700 Roppers Building					ker Wood, Ph.D.		
Pittsburgh, PA 15219-1818 NAME Telephone: (412) 471-8815 51,027							
					ON NUMBER		

PATENT APPLICATION/PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:	ATTORNEY'S DOCKET NUMBER
Duncan J. STEWART, David COURTMAN and Golnaz KAROUBI	3998-051955
PCT/CA2003/002008	
ENTITLED	
"ENCAPSULA	TED CELL THERAPY"

To MAIL STOP PCT
Attention: DO/EO/US
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

EXPRESS MAIL CERTIFICATE

"Express Mail" Label Number <u>EL971224814US</u>

Date of Deposit June 24, 2005

I hereby certify that the following <u>attached</u> papers or fees

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/
ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER
35 U.S.C. 371 (original and two (2) copies) and check in amount
of \$2,080.00 for filing fee and surcharge for late Declaration
LETTER RECOGNIZING ATTORNEYS
PRELIMINARY AMENDMENT with ABSTRACT
WO 2004/058305- FRONT PAGE with ABSTRACT, SPECIFICATION,
CLAIMS, DRAWINGS, SEQUENCE LISTING and SEARCH REPORT (73 pp.)

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450.

Nora Ann Pastrick
(Typed name of person mailing paper or fee)

Machine Gua Latrick
(Signature of person mailing paper or fee)

JC09 Rec'd PCT/PTO 24 JUN 2005

Customer No. 28289

Application No. Not Yet Assigned Paper Dated: June 24, 2005

In Reply to USPTO Correspondence of N/A

Attorney Docket No. 3998-051955

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

: Not Yet Assigned

Applicants

Duncan J. STEWART et al.

Filed

: Concurrently Herewith

Title

ENCAPSULATED CELL THERAPY

International Application

No. PCT/CA2003/002008

International Filing Date

: 24 December 2003

Priority Date Claimed

: 24 December 2002

Customer Number

28289

MAIL STOP PCT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

LETTER RECOGNIZING ATTORNEYS

Sir:

Enclosed are appropriate papers for initiating the national phase of the above-identified PCT application, comprising a specification, claims, drawings and search report. A Preliminary Amendment is also enclosed.

Please accept the application for purposes of granting a filing date and recognize William H. Logsdon, Richard L. Byrne and Gwen R. Acker Wood, Ph.D., Registration Nos. 22,132, 28,498 and 51,027, respectively, as attorneys in this application, pending the filing of a formal Declaration and Power of Attorney.

Kindly direct all communications relating to this application to William H. Logsdon.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON ORKIN & HANSON, P.C.

Bv

Gwen R. Acker Wood, Ph.D., Reg. No. 51,027

Attorney for Applicants 700 Koppers Building 436 Seventh Avenue Pittsburgh, PA 15219-1818

Telephone: 412/471-8815 Facsimile: 412/471-4094